NuVasive, Inc.

NasdaqGS:NUVA Aktierapport

Börsvärde: US$2.1b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

NuVasive Tidigare resultatutveckling

Tidigare kriterier kontrolleras 1/6

NuVasive s intäkter har minskat med en genomsnittlig årlig takt på -33%, medan Medical Equipment -branschen såg intäkter på växande på 13.6% årligen. Intäkterna har varit växande med en genomsnittlig takt på 2.1% per år. NuVasive s avkastning på eget kapital är 3.2% och den har en nettomarginal på 2.3%.

Viktig information

-33.00%

Tillväxttakt i vinsten

-33.18%

Tillväxttakt för EPS

Medical Equipment Tillväxt i branschen8.90%
Intäkternas tillväxttakt2.10%
Avkastning på eget kapital3.19%
Nettomarginal2.32%
Senaste uppdateringen av resultatet30 Jun 2023

Senaste uppdateringar av tidigare prestationer

Recent updates

Analysartikel • Apr 18

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysartikel • Jan 24

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

While NuVasive, Inc. ( NASDAQ:NUVA ) might not be the most widely known stock at the moment, it saw a significant share...
Analysartikel • Dec 31

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Key Insights NuVasive's estimated fair value is US$60.8 based on 2 Stage Free Cash Flow to Equity Current share price...
Analysartikel • Dec 05

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
Analysartikel • Nov 13

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysartikel • Sep 22

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Does the September share price for NuVasive, Inc. ( NASDAQ:NUVA ) reflect what it's really worth? Today, we will...
Analysartikel • Sep 01

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...
Seeking Alpha • Aug 17

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

NuVasive modestly exceeded topline expectations for Q2, but core U.S. growth is still soft, particularly when factoring in the above-average growth of the cervical disc business. In a challenging spine care market, NuVasive looks at risk of "drifting", with neither the above-average revenue growth nor strong core margins that med-tech investors often seek. NuVasive isn't beyond hope - the cervical franchise looks strong, Pulse is still a long-term opportunity, and NUVA still has good overall share, but it needs to be more dynamic. The shares are undervalued below the mid-$60s, but the stock badly needs a catalyst to get investors excited about the name again. Valuation alone doesn't move stocks - expensive stocks don't fall just because they're expensive, and cheap stocks don't rise just because investors suddenly decide they're too cheap. In most cases, it requires some sort of driver or catalyst to get investors to reconsider a name, and that's a challenge for NuVasive (NUVA) today. The shares of this spine-focused medical device company do look undervalued today, but they've looked undervalued for a while. Although the shares have slightly outperformed the broader medical device space since my last update and outperformed names like Alphatec (ATEC) and SeaSpine (SPNE) while recently starting to lag Globus (GMED), they still haven't done anything to celebrate over the last five years. NuVasive is salvageable, but the company's management needs to offer more than what is apparent today - investors need to have a reason to believe in growth drivers beyond the cervical portfolio and that long-awaited margin improvement will actually materialize. While this could happen, there's a real risk that "okay, but not great" growth and margins keep a lid on the share price performance at NuVasive. Second Quarter Results - A Little Better On The Topline, But Not Really Great Overall NuVasive's second quarter was, at best, "mixed" and not really the sort of quarter that's going to shift sentiment in a meaningfully positive way. Revenue rose 8% and beat expectations by close to 2%. U.S. spine ("Hardware") revenue rose 3% on improved case volumes, and that was better than the declines at Johnson & Johnson (JNJ) and Stryker (SYK) and on pace with Globus, but with the cervical portfolio growing more than 20%, there's still weakness in the core portfolio. U.S. Surgical revenue rose 6%, with improved Pulse sales offsetting a year-over-year decline in biologics, while international sales rose more than 20% in constant currency. Gross margin declined 120bp to 72.4%, missing by 80bp, and the med-tech sector is still seeing noticeable negative impacts from supply chain issues (components, shipping, et al.). Operating income declined 1%, missing by 3%, and operating margin fell 80bp to 13.1%, missing by more than 30bp. Management basically held the line on guidance, though hitting the full year target of 9% to 11% constant currency growth is going to require acceleration from here. Ongoing post-pandemic normalization and some new product introductions can support that acceleration, but the overall U.S. spine market isn't looking especially robust right now. Waiting For Something To Disrupt The Business (In A Good Way) It's been a long, frustrating wait for real momentum in NuVasive's business, and it does explain, at least in part, why these shares have been a laggard over the longer term (five-year, 10-year, and 15-year comparisons to the sector). Revenue growth over the last 15 years hasn't been bad (around 15% a year), but that growth has slowed considerably in the last five years (to the low single digits). Salesforce defections have been a recurrent problem over the years, and relative to companies like Globus, I think you can argue that NuVasive has under-innovated, and that's taking a toll on core franchises like the lateral interbody fusion business. The company was also certainly slow to recognize the importance of robotics, and with the Pulse robotic system no longer expected to achieve first-in-human use this year, that timeline is slipping further. NuVasive has also struggled to hit even its revised operating margin targets. Where the company once talked about the possibility of 25% or better operating margins (some rivals have achieved high-20%s for margins), more recently the goal has been on the order of 20%, but the company is still well short of that - operating margin was just over 13% in the second quarter, and the most bullish sell-side projections I've seen don't call for 20% margins at any point over the next five years. On the positive side, the company's cervical disc business is growing well, and I still see strong growth potential here, as NuVasive's discs are the only ones clinically proven to produce better outcomes than fusion surgery. I also believe the full Pulse platform (not just the robotic aspect, but the planning, neuromonitoring, imaging, and navigation capabilities) can be a significant growth driver, with an addressable market opportunity of around $1.5B (against expected total revenue of around $1.2B in FY'22).
Analysartikel • Aug 11

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Aug 03

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

NuVasive press release (NASDAQ:NUVA): Q2 Non-GAAP EPS of $0.47 misses by $0.09. Revenue of $310.5M (+5.3% Y/Y) beats by $4.12M.
Seeking Alpha • Jun 13

NuVasive: Industry Tailwinds More Than Fairly Priced

NuVasive has solid underpinnings as a potentially defensive play, with strengthening platform economics. Industry tailwinds also apply to the company, although it needs an above market growth pattern to adequately reward shareholders. We've priced NUVA at $49–$53 noting the stock may be fully priced at its current levels.
Analysartikel • Jun 01

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

In this article we are going to estimate the intrinsic value of NuVasive, Inc. ( NASDAQ:NUVA ) by estimating the...
Analysartikel • May 11

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...
Analysartikel • Apr 20

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysartikel • Mar 30

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive, Inc. ( NASDAQ:NUVA ), is not the largest company out there, but it saw a double-digit share price rise of...
Seeking Alpha • Mar 01

NuVasive's Turnaround Story Needs A Boost From Better Results

NuVasive managed a modest beat in Q4'21 and the initial guide for 2022 was okay, but the company needs to start showing clear evidence of market share regrowth. The core technology platform, including X360, is sound and newer opportunities like Simplify and Pulse can add meaningfully to revenue growth, but execution is a key unknown. Weak margins have challenged NuVasive for years, and this remains an important driver of earnings/cash flow and sentiment. NuVasive looks undervalued, but sentiment won't shift until the share losses reverse to share gains and there's evidence of positive operating leverage.
Analysartikel • Dec 28

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
Analysartikel • Dec 02

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

NuVasive, Inc. ( NASDAQ:NUVA ), might not be a large cap stock, but it saw significant share price movement during...
Analysartikel • Nov 11

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysartikel • Oct 21

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of NuVasive, Inc...
Analysartikel • Sep 29

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...
Analysartikel • Aug 18

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

NuVasive, Inc. ( NASDAQ:NUVA ), is not the largest company out there, but it saw significant share price movement...
Seeking Alpha • Aug 12

NuVasive Still Getting No Love With COVID-19 And Competitive Worries

NuVasive produced its second straight quarter with a double-digit operating income beat, but in-line guidance and fears of renewed COVID-19 lockdowns seem to be weighing on the shares. New product innovation appears to be driving revenue growth, with Modulus and the cervical portfolio performing well, and Pulse about to launch. COVID-19 remains a clear short-term risk, but I believe NuVasive's opportunity to regain share and drive operating leverage is undervalued today.
Analysartikel • Jul 27

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysartikel • Jun 17

Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Today we will run through one way of estimating the intrinsic value of NuVasive, Inc. ( NASDAQ:NUVA ) by taking the...
Analysartikel • May 30

Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Analysartikel • May 12

Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

The share price of NuVasive, Inc. ( NASDAQ:NUVA ) has increased significantly over the past few years. However, the...
Analysartikel • Mar 30

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysartikel • Mar 09

Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

NuVasive, Inc. ( NASDAQ:NUVA ), might not be a large cap stock, but it received a lot of attention from a substantial...
Analysartikel • Feb 16

Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Analysartikel • Jan 26

A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

How far off is NuVasive, Inc. ( NASDAQ:NUVA ) from its intrinsic value? Using the most recent financial data, we'll...
Analysartikel • Jan 05

What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

NuVasive, Inc. ( NASDAQ:NUVA ) shareholders should be happy to see the share price up 11% in the last month. But in...

Fördelning av intäkter och kostnader

Hur NuVasive tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.

Resultat- och intäktshistorik

NasdaqGS:NUVA Intäkter, kostnader och resultat (USD Millions )
DatumIntäkterIntäkterG+A KostnaderFoU-kostnader
30 Jun 231,22628653102
31 Mar 231,21920650100
31 Dec 221,2024063499
30 Sep 221,199-2063698
30 Jun 221,174-4062898
31 Mar 221,159-3762494
31 Dec 211,139-6461093
30 Sep 211,129-2659489
30 Jun 211,153259486
31 Mar 211,062-5056384
31 Dec 201,051-3754780
30 Sep 201,069-956377
30 Jun 201,065-457075
31 Mar 201,1536159673
31 Dec 191,1686561172
30 Sep 191,1464859370
30 Jun 191,1275258167
31 Mar 191,1164957465
31 Dec 181,1021257662
30 Sep 181,0852456857
30 Jun 181,0604155355
31 Mar 181,0384254653
31 Dec 171,0278254050
30 Sep 171,0276454751
30 Jun 171,0193555450
31 Mar 179965354950
31 Dec 169623753448
30 Sep 169064251044
30 Jun 168675148940
31 Mar 168343146837
31 Dec 158116645736
30 Sep 158006245437
30 Jun 157904745737
31 Mar 157773346038
31 Dec 14762-1745737
30 Sep 14749-1845736
30 Jun 14728-944634
31 Mar 14703-1143332
31 Dec 13685842032
30 Sep 13660-140333
30 Jun 13639-638933
31 Mar 13628337735
31 Dec 12620337235
30 Sep 12605-436834

Kvalitetsintäkter: NUVA har en stor engång förlust av $16.9M {1 månader till 30th June, 2023 1 månader) 30th June, 2023.

Växande vinstmarginal: NUVA blev lönsam tidigare.

Fritt kassaflöde vs resultatanalys

Analys av tidigare vinsttillväxt

Resultatutveckling: NUVA s intäkter har minskat med 33% per år under de senaste 5 åren.

Accelererande tillväxt: NUVA har blivit lönsamt under det senaste året, vilket gör det svårt att jämföra vinsttillväxttakten med 5-årsgenomsnittet.

Resultat vs industri: NUVA har blivit lönsamt under det senaste året, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Medical Equipment branschen ( 14.8% ).

Avkastning på eget kapital

Hög ROE: NUVA s avkastning på eget kapital ( 3.2% ) anses vara låg.

Avkastning på tillgångar

Avkastning på sysselsatt kapital

Upptäck starka bolag som tidigare presterat bra

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2023/09/02 10:50
Aktiekurs vid dagens slut2023/08/31 00:00
Intäkter2023/06/30
Årlig intjäning2022/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

NuVasive, Inc. bevakas av 28 analytiker. 12 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
null nullArgus Research Company
Jeffrey JohnsonBaird
Adam FeinsteinBarclays